Table 2.
Treatment exposure
| Treatment exposure | HBV analysis populationa |
HCV analysis populationa |
Nonviral population |
Safety population |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| atezo + bev (n = 108) |
sorafenib (n = 42) | atezo + bev (n = 37) |
sorafenib (n = 21) | atezo + bev (n = 191) |
sorafenib (n = 98) | atezo + bev (n = 329) |
sorafenib (n = 156) | |||||
| atezo | bev | atezo | bev | atezo | bev | atezo | bev | |||||
| Treatment duration, median | ||||||||||||
| (range) months | 7.6 (0–16) | 7.0 (0–15) | 3.9 (1–13) | 7.6 (0–16) | 7.2 (0–16) | 4.1 (0–10) | 6.9 (0–15) | 6.3 (0–15) | 2.1 (0–16) | 7.4 (0–16) | 6.9 (0–16) | 2.8 (0–16) |
| Treatment duration, n (%) | ||||||||||||
| 0 to <3 months | 13 (12) | 14 (13) | 19 (45) | 5 (14) | 5 (14) | 9 (43) | 58 (30) | 60 (31) | 64 (65) | 75 (23) | 78 (24) | 89 (57) |
| 3 to <6 months | 20 (19) | 24 (22) | 8 (19) | 5 (14) | 8 (22) | 3 (14) | 24 (13) | 28 (15) | 11 (11) | 48 (15) | 58 (18) | 22 (14) |
| 6 to <9 months | 38 (35) | 37 (34) | 11 (26) | 12 (32) | 11 (30) | 7 (33) | 53 (28) | 51 (27) | 12 (12) | 100 (30) | 97 (29) | 28 (18) |
| 9 to <12 months | 26 (24) | 23 (21) | 2 (5) | 10 (27) | 9 (24) | 2 (10) | 41 (21) | 38 (20) | 8 (8) | 76 (23) | 69 (21) | 12 (8) |
| ≥12 months | 11 (10) | 10 (9) | 2 (5) | 5 (14) | 4 (11) | 0 | 15 (8) | 14 (7) | 3 (3) | 30 (9) | 27 (8) | 5 (3) |
atezo, atezolizumab; bev, bevacizumab; HBV, hepatitis B virus; HCV, hepatitis C virus.
a
The HBV and HCV analysis populations were not mutually exclusive (7 patients treated with atezo + bev and 5 patients treated with sorafenib were included in both analysis populations).